JNJ-40411813
CR108943
Phase 2 small_molecule completed
Quick answer
JNJ-40411813 for Focal Onset Seizures is a Phase 2 program (small_molecule) at Janssen Cilag International NV with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen Cilag International NV
- Indication
- Focal Onset Seizures
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed